Axinn Obtains Favorable Decision in FDA Suit
January 15, 2013
Axinn secured a favorable outcome for client Alvogen Inc. in ViroPharma Inc’s case against the U.S. Food and Drug Administration regarding generic forms of the antibiotic Vancocin (vancomycin). The Axinn team assisted Alvogen Inc. in intervening on the side of the government in order to allow Alvogen to continue to market its generic vancomycin product under its approved Abbreviated New Drug Application.
Judge Huvelle’s Memorandum Opinion stated that “the FDA acted well within its discretion in denying three-year exclusivity to ViroPharma and in approving the ANDAs of intervenor-defendants.”
To subscribe to our publications, click here.
Featured Insights
Featured Insights
DC Bar: The DOJ's New Antitrust Whistleblower Rewards Program: An Overview and the Road Ahead
Speaking Engagement
Antitrust
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
What’s Up? Enforcement Updates From the Middle East and Africa
Podcast
Antitrust
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Lexology In-Depth: Intellectual Property and Antitrust (2026)
Byline Articles
Intellectual Property
Tracking The Rare 'Quick Look' Win In FTC's Zillow-Redfin Suit
Byline Articles
Antitrust
Gleiss Lutz Annual Antitrust Law Conference
Speaking Engagement
Antitrust
What Top Law Firms Say New Lawyers Need in the AI Era
Media Mentions
What’s the Role of Communications Strategy in M&A? How Public Affairs Impacts Antitrust
Podcast
Antitrust
